239 related articles for article (PubMed ID: 36551398)
21. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
22. Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing
Oliva A; Volpicelli L; Di Bari S; Curtolo A; Borrazzo C; Cogliati Dezza F; Cona A; Agrenzano S; Mularoni A; Trancassini M; Mengoni F; Stefani S; Raponi G; Venditti M
JAC Antimicrob Resist; 2022 Dec; 4(6):dlac121. PubMed ID: 36506890
[TBL] [Abstract][Full Text] [Related]
23. A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.
Sy SKB; Zhuang L; Xia H; Schuck VJ; Nichols WW; Derendorf H
Clin Microbiol Infect; 2019 Jul; 25(7):904.e9-904.e16. PubMed ID: 30394361
[TBL] [Abstract][Full Text] [Related]
24. Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.
Papp-Wallace KM; Zeiser ET; Becka SA; Park S; Wilson BM; Winkler ML; D'Souza R; Singh I; Sutton G; Fouts DE; Chen L; Kreiswirth BN; Ellis-Grosse EJ; Drusano GL; Perlin DS; Bonomo RA
J Infect Dis; 2019 Jul; 220(4):666-676. PubMed ID: 31099835
[TBL] [Abstract][Full Text] [Related]
25. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
[TBL] [Abstract][Full Text] [Related]
26. Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections.
Gatti M; Cojutti PG; Pascale R; Tonetti T; Laici C; Dell'Olio A; Siniscalchi A; Giannella M; Viale P; Pea F
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827249
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run.
Gatti M; Viale P; Pea F
J Antimicrob Chemother; 2024 Jan; 79(1):195-199. PubMed ID: 38019676
[TBL] [Abstract][Full Text] [Related]
28. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
29. Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887225
[TBL] [Abstract][Full Text] [Related]
30. The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study.
Xu Y; Luo X; Yuan B; Liang P; Liu N; Dong D; Ge W; Gu Q
J Antimicrob Chemother; 2024 Apr; 79(4):820-825. PubMed ID: 38366379
[TBL] [Abstract][Full Text] [Related]
31. [Chinese expert consensus on the management of lower respiratory tract infections of
Pulmonary Infection Assembly of Chinese Thoracic Society
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044
[TBL] [Abstract][Full Text] [Related]
32. A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis.
Gatti M; Tedeschi S; Trapani F; Ramirez S; Mancini R; Giannella M; Viale P; Pea F
Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009906
[TBL] [Abstract][Full Text] [Related]
33. Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections.
Gatti M; Campoli C; Latrofa ME; Ramirez S; Sasso T; Mancini R; Caramelli F; Viale P; Pea F
Pediatr Infect Dis J; 2023 Nov; 42(11):975-982. PubMed ID: 37523585
[TBL] [Abstract][Full Text] [Related]
34. Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives.
Bavaro DF; Belati A; Diella L; Stufano M; Romanelli F; Scalone L; Stolfa S; Ronga L; Maurmo L; Dell'Aera M; Mosca A; Dalfino L; Grasso S; Saracino A
Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34072342
[TBL] [Abstract][Full Text] [Related]
35. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Efficacy of Optimized Two-Step-Administration Therapy with Ceftazidime/Avibactam for Treating Extensively Drug-Resistant Pseudomonas aeruginosa Pulmonary Infections: a Pharmacokinetic/Pharmacodynamic Analysis.
Kang Y; Cui J
Jpn J Infect Dis; 2023 Jan; 76(1):1-6. PubMed ID: 35908879
[TBL] [Abstract][Full Text] [Related]
37. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
[TBL] [Abstract][Full Text] [Related]
38. Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.
Das S; Zhou D; Nichols WW; Townsend A; Newell P; Li J
Eur J Clin Pharmacol; 2020 Mar; 76(3):349-361. PubMed ID: 31836928
[TBL] [Abstract][Full Text] [Related]
39. Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant
Lopez-Montesinos I; Montero MM; Domene-Ochoa S; López-Causapé C; Echeverria D; Sorlí L; Campillo N; Luque S; Padilla E; Prim N; Grau S; Oliver A; Horcajada JP
Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358110
[TBL] [Abstract][Full Text] [Related]
40. In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales.
Ozyurt OK; Tufanoglu P; Cetinkaya O; Ozhak B; Yazisiz H; Ongut G; Turhan O; Ogunc D
Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
